Zobrazeno 1 - 10 of 35 pro vyhledávání: '"J. Steven Jacobsen"'
1
Akademický článek
Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate
Autor: Gregory eHook, J. Steven Jacobsen, Kenneth eGrabstein, Mark eKindy, Vivian eHook
Publikováno v: Frontiers in Neurology, Vol 6 (2015)
There currently is no therapeutic drug treatment for traumatic brain injury (TBI) despite decades of experimental clinical trials. This may be because the mechanistic pathways for improving TBI outcomes have yet to be identified and exploited. As suc
Externí odkaz: https://doaj.org/article/b8414a0b3e2b47378de5943d9a22db37
Zobrazit plný text záznamu
2
Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid
Autor: Janice S. Gilsdorf, Zhihui Yang, Bharani Thangavelu, Claudia S. Robertson, Deborah A. Shear, Kevin K.W. Wang, George Anis Sarkis, Vivian Hook, Brittany N Abbatiello, Gregory Hook, J. Steven Jacobsen, Angela M. Boutté
Publikováno v: J Neurotrauma
Cathepsin B (CatB), a lysosomal cysteine protease, is important to brain function and may have dual utility as a peripheral biomarker of moderate-severe traumatic brain injury (TBI). The present study determined levels of pro- and mature (mat) CatB p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcf77cc3204b7340077de96ab274b4a6
https://doi.org/10.1089/neu.2019.6537
Zobrazit plný text záznamu
3
Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease
Autor: J. Steven Jacobsen, Albert J. Robichaud, Kim Ji-In
Publikováno v: Burger's Medicinal Chemistry and Drug Discovery
Recognized as the most common of the neurodegenerative disorders, Alzheimer's disease (AD) affects greater than 18 million people worldwide and is predicted to become the largest socioeconomic burden of the twenty-first century. The underlying mechan
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e564793e257af940b40aea28da3c2cbb
https://doi.org/10.1002/0471266949.bmc249
Zobrazit plný text záznamu
5
Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate
Autor: Mark S. Kindy, Vivian Hook, Kenneth H. Grabstein, Gregory Hook, J. Steven Jacobsen
Publikováno v: Frontiers in Neurology, Vol 6 (2015)
Frontiers in Neurology
There currently is no therapeutic drug treatment for traumatic brain injury (TBI) despite decades of experimental clinical trials. This may be because the mechanistic pathways for improving TBI outcomes have yet to be identified and exploited. As suc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1af275ce005938b6012d5a10d93ac2
https://doi.org/10.3389/fneur.2015.00178
Zobrazit plný text záznamu
6
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease
Autor: Menelas N. Pangalos, J. Steven Jacobsen, Peter H. Reinhart
Publikováno v: NeuroRX. 2:612-626
Summary: Alzheimer’s disease is a progressive neurodegenerative disorder and the leading cause of dementia in the Western world. Postmortem, it is characterized neuropathologically by the presence of amyloid plaques, neurofibrillary tangles, and a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f400b40f30b9a7cea10e437185e8a0a0
https://doi.org/10.1602/neurorx.2.4.612
Zobrazit plný text záznamu
7
Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease
Autor: Karen L. Marquis, Suzan Aschmies, Hua Zhou, Robert Martone, Kevin Atchison, June Sonnenberg-Reines, Anthony Kreft, Menelas N. Pangalos, Thomas A. Comery, J. Steven Jacobsen, George Diamantidis, Xiaohai Gong
Publikováno v: The Journal of Neuroscience. 25:8898-8902
Transgenic mice (Tg2576) overexpressing the Swedish mutation of the human amyloid precursor protein display biochemical, pathological, and behavioral markers consistent with many aspects of Alzheimer's disease, including impaired hippocampal function
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44b492d9ca4d6361b6a9a861cd42e865
https://doi.org/10.1523/jneurosci.2693-05.2005
Zobrazit plný text záznamu
8
Commentary on 'A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.' A proposal to increase participation in Alzheimer's disease clinical trials
Autor: J. Michael Ryan, Greg Schneider, J. Steven Jacobsen
Publikováno v: Alzheimer's & Dementia. 5:140-142
Among the many contributions of Leon Thal to the field of Alzheimer’s disease (AD) research was his leadership in developing the clinical trial network required for accelerating the testing of new potential therapies. He co-founded the Alzheimer’
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a312c883dc52e5811decbd311d120c8d
https://doi.org/10.1016/j.jalz.2009.01.004
Zobrazit plný text záznamu
9
Altered binding of mutated presenilin with cytoskeleton-interacting proteins1
Autor: George Merz, Jane M. Johnston, Jiliu Xu, Leszek Kotula, Amit A. Johnsingh, J. Steven Jacobsen, Nikolaos Tezapsidis
Publikováno v: FEBS Letters. 465:53-58
The majority of familial Alzheimer’s disease (AD) cases are linked to mutations on presenilin 1 and 2 genes (PS1 and PS2). The normal function of the proteins and the mechanisms underlying early-onset AD are currently unknown. To address this, we s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abba9e565bdabe66eedf569e063ebbec
https://doi.org/10.1016/s0014-5793(99)01664-6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje